The future of cell therapy for acute myocardial infarction

Nature Clinical Practice. Cardiovascular Medicine
Noel M Caplice

Abstract

Initial clinical trials of bone-marrow-derived mononuclear cells after acute myocardial infarction have shown improvement in a number of cardiac indices, including left ventricular systolic function, infarct size, stroke volume, and coronary blood flow. Functional improvements observed in cell therapy studies have been modest, with augmentation of left ventricular function in the range of 6-8%. Nevertheless, these studies have generated considerable debate on a number of issues, including the efficacy of specific cell populations, logistics of cell harvesting and isolation, and, most importantly, the mechanism of cell therapy benefit. With the field on the threshold of large-scale, randomized, controlled clinical trials, additional questions, such as the following, must be asked. Can cell therapy procedures be simplified? Can therapeutic effects be obtained earlier after myocardial infarction? Is cell harvesting a necessary component of cell therapy or can endogenous cells be mobilized sufficiently to obviate the need for processing exogenous cells? In an era when interventional devices are increasingly used in therapeutic approaches to acute myocardial infarction, can current cell therapy practice be integrated with interventi...Continue Reading

References

Mar 10, 2004·Cell·Amy J Wagers, Irving L Weissman
Aug 21, 2004·Arteriosclerosis, Thrombosis, and Vascular Biology·Tongrong HeZvonimir S Katusic
Sep 11, 2004·Circulation Research·Francisco Fernández-AvilésAna Sánchez
Apr 5, 2005·American Journal of Physiology. Heart and Circulatory Physiology·Tongrong HeZvonimir S Katusic
Nov 3, 2005·Nature Clinical Practice. Cardiovascular Medicine·Noel M CapliceJorge R Alegria

❮ Previous
Next ❯

Citations

Nov 21, 2007·Journal of Cardiothoracic Surgery·Hilal Al Sabti
Mar 10, 2012·Knee Surgery, Sports Traumatology, Arthroscopy : Official Journal of the ESSKA·Kivanc AtesokEmil Schemitsch
Dec 16, 2006·Endothelium : Journal of Endothelial Cell Research·Brendan DoyleNoel M Caplice
Apr 25, 2009·Ageing Research Reviews·Lan SunGuanhua Du
May 26, 2009·Journal of Molecular and Cellular Cardiology·Lucia FormigliDaniele Bani
Sep 19, 2008·Journal of Cellular and Molecular Medicine·Massimo BonacchiDaniele Bani
May 7, 2009·Annals of the New York Academy of Sciences·Daniele BaniSandra Zecchi-Orlandini
Aug 12, 2009·Vox Sanguinis·L SensebéR Giordano
Jan 19, 2007·Nature Clinical Practice. Cardiovascular Medicine·Pat MetharomNoel M Caplice

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiac Regeneration

Cardiac regeneration enables the repair of irreversibly damaged heart tissue using cutting-edge science, including stem cell and cell-free therapy. Discover the latest research on cardiac regeneration here.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.